Form 8-K - Current report:
SEC Accession No. 0001104659-25-005648
Filing Date
2025-01-23
Accepted
2025-01-23 16:42:03
Documents
14
Period of Report
2025-01-23
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm254291d1_8k.htm   iXBRL 8-K 29114
2 EXHIBIT 99.1 tm254291d1_ex99-1.htm EX-99.1 21002
  Complete submission text file 0001104659-25-005648.txt   231965

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sls-20250123.xsd EX-101.SCH 3042
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sls-20250123_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sls-20250123_pre.xml EX-101.PRE 22378
16 EXTRACTED XBRL INSTANCE DOCUMENT tm254291d1_8k_htm.xml XML 3688
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 25550656
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)